Immunosuppressive therapy of patients with pemphigus with ineffectiveness of systemic corticosteroids

Therapy of patients with pemphigus vulgaris with systemic corticosteroids may not be effective enough or lead to the development of severe adverse events that make it necessary to reduce the dose of corticosteroid. In such cases, it is possible to use the immunosuppressants. The literature review analyzes case reports and the results of studies that evaluated the effectiveness and safety of drugs used for immunosuppressive therapy of patients with pemphigus vulgaris. The drugs doses, the studies design, and criteria for evaluating the effectiveness of therapy in patients with pemphigus are considered. As a result of the analysis, it was shown that case reports and non-compatarive studies demonstrate the effectiveness and steroid-sparing effect of azathioprine, dapsone, methotrexate, mycophenolate mofetil, cyclosporine and cyclophosphamide in the treatment of patients with pemphigus vulgaris. Nevertheless, comparative studies show an increase in the effectiveness of therapy in patients with pemphigus and a faster achievement of therapeutic effect when prescribing cyclophosphamide, but not azathioprine, dapsone, methotrexate, mycophenolate mofetil or cyclosporine. However, the toxicity of cyclophosphamide limits its use in pemphigus. Thus, adjuvant drugs can be used in the treatment of patients with pemphigus in situations where it is not possible to reduce the dose of a systemic corticosteroid, especially in cases of severe adverse events of corticosteroid therapy.

• Publication year

  2024

• Venue

  Vestnik Dermatologii i Venerologii

• Publication date

  2024-11-22

• Fields of study

  Not labeled

• Identifiers
  DOI 10.25208/vdv16808
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Taiwanese dermatological association (TDA) consensus for the management of pemphigus.

  2022cited by this paper
• A randomised clinical trial to assess the adjuvant potential of methotrexate to corticosteroids in mucosal or limited mucocutaneous pemphigus vulgaris

  2022cited by this paper
• Oral Pemphigus Vulgaris Treatment with Corticosteroids and Azathioprine: A Long-Term Study in Shiraz, Iran

  2022cited by this paper
• Epidemiology of Pemphigus

  2021cited by this paper
• Aggressive refractory pemphigus vulgaris that responded to plasmapheresis: a case report

  2020cited by this paper
• Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)

  2020cited by this paper
• A Comparison of Azathioprine and Mycophenolate Mofetil as Adjuvant Drugs in Patients with Pemphigus: A Retrospective Cohort Study

  2019cited by this paper
• Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts.

  2018cited by this paper
• Identification of factors associated with treatment refractoriness of oral lesions in pemphigus vulgaris

  2017cited by this paper
• Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review.

  2017cited by this paper
• The Prediction and Monitoring of Toxicity Associated with Long-Term Systemic Glucocorticoid Therapy

  2015cited by this paper
• The role of adjuvant therapy in pemphigus: A systematic review and meta-analysis.

  2015cited by this paper
• Dapsone in the treatment of pemphigus vulgaris: adverse effects and its importance as a corticosteroid sparing agent*

  2015cited by this paper
• Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus

  2015cited by this paper
• Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients

  2013cited by this paper
• Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris

  2012cited by this paper
• Evaluation of mycophenolate mofetil as a steroid‐sparing agent in pemphigus: a randomized, prospective study

  2012cited by this paper
• Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris.

  2012cited by this paper
• High dose oral prednisone vs. prednisone plus azathioprine for the treatment of oral pemphigus: a retrospective, bi‐centre, comparative study

  2011cited by this paper
• Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review.

  2011cited by this paper
• Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid

  2009cited by this paper
• Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris.

  2008cited by this paper
• Dose-related patterns of glucocorticoid-induced side effects

  2008cited by this paper
• Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris.

  2007cited by this paper
• Efficacy and Safety of Cyclophosphamide, Azathioprine, and Cyclosporine (Ciclosporin) as Adjuvant Drugs in Pemphigus Vulgaris

  2007cited by this paper
• Fracture risk with intermittent high-dose oral glucocorticoid therapy.

  2007cited by this paper
• Use of oral corticosteroids and the risk of acute myocardial infarction.

  2007cited by this paper
• Glucocorticoid use, other associated factors, and the risk of tuberculosis.

  2006cited by this paper
• A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus.

  2006cited by this paper
• Intravenous dexamethasone‐cyclophosphamide pulse therapy in comparison with oral methylprednisolone‐azathioprine therapy in patients with pemphigus: Results of a multicenter prospectively randomized study

  2005cited by this paper
• Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris.

  2005cited by this paper
• Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus.

  2003cited by this paper
• Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil.

  2003cited by this paper
• An evaluation of the usefulness of mycophenolate mofetil in pemphigus

  2003cited by this paper
• Steroids and risk of upper gastrointestinal complications.

  2001cited by this paper
• An unusual case of pemphigus vulgaris presenting as bilateral foot ulcers

  2000cited by this paper
• Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus.

  2000cited by this paper
• Methotrexate as an adjuvant treatment for pemphigus vulgaris.

  1999cited by this paper
• Mycophenolate is effective in the treatment of pemphigus vulgaris.

  1999cited by this paper
• Mycophenolate mofetil in autoimmune and inflammatory skin disorders.

  1999cited by this paper
• The adjuvant therapy of pemphigus. An update.

  1996cited by this paper
• The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: preliminary study.

  1994cited by this paper
• Treatment of pemphigus vulgaris with cyclosporine. .

  1990cited by this paper
• Risk of infectious complications in patients taking glucocorticosteroids.

  1989cited by this paper
• Treatment of nine cases of pemphigus vulgaris with cyclosporine.

  1988cited by this paper
• Use of cyclophosphamide in azathioprine failures in pemphigus.

  1987cited by this paper
• TREATMENT OF PEMPHIGUS WITH CORTICOSTEROIDS AND CYCLOPHOSPHAMIDE

  1979cited by this paper
• Dapsone in the treatment of pemphigus vulgaris.

  1978cited by this paper
• Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975.

  1977cited by this paper
• Pemphigus controlled by dapsone

  1976cited by this paper
• TREATMENT OF PEMPHIGUS WITH CYCLOPHOSPHAMIDE

  1975cited by this paper
• Azathioprine for pemphigus and pemphigoid—a 4 year follow‐up

  1974cited by this paper
• Treatment of Pemphigus and Pemphigoid with Azathioprine

  1973cited by this paper
• Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid.

  1972cited by this paper
• Methotrexate and prednisone in pemphigus vulgaris. Therapeutic results obtained in 36 patients between 1961 and 1970.

  1972cited by this paper
• IMMUNOSUPPRESSANTS IN THE TREATMENT OF PEMPHIGUS

  1970cited by this paper
• Pemphigus vulgaris successfully treated with cyclophosphamide.

  1969cited by this paper

• No citing papers are available for this paper.